New research suggests that people who come off new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional diet and exercise regimens.
Findings released in a leading medical journal points out that while overweight people often shed about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People using these drugs should be aware of the potential of fast rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to original mass in about a year and a half.
Comparing Approaches
The research, which looked at 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods.
The team point out that individuals who lose weight through dieting usually experience a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Quick Rebound
Nutrition scientists believe the way of the drugs accounts for the heightened weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
The NHS suggest the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, considering the high risk of weight regain, the treatment might need to be life-long.
This perspective is supported by pharmaceutical companies, who state that the results "emphasize the persistent nature of excess weight," similar to managing conditions like high blood pressure.
Patient Accounts
Users who have stopped the jabs describe a sudden resurgence of appetite.
"It was like something flipping and you're instantly ravenous," recalled a patient.
The struggle is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and long-term success relies on combined lifestyle management.
